Patents by Inventor Brian Santich

Brian Santich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multimodal fluorine-CY3/5/7-DOTA-hapten compositions, diagnostics, fluorescence guided surgery and radioimmunotherapy
    Patent number: 12533428
    Abstract: The present disclosure provides compositions and methods for the detection, and treatment of cancer. Specifically, the compositions of the present technology include multimodal fluorine-cyanine-DOTA-hapten compositions that may be complexed with a radioisotope (e.g., 175Lu). Also disclosed herein are methods of using the fluorine-cyanine-DOTA-hapten compositions of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: January 27, 2026
    Assignees: Memorial Sloan Kettering Cancer Center, Cornell University
    Inventors: Nai-Kong V. Cheung, Steven M. Larson, Sarah Cheal, Richard Ting, Hari Krishna Kommidi, Feifei An, Brian Santich
  • ANTI-TSHR MULTI-SPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20240415888
    Abstract: The present technology provides anti-Thyroid Stimulating Hormone Receptor (TSHR) multi-specific (e.g., bispecific) immunoglobulin-related compositions and methods of using the same to treat TSHR-associated pathologies including, but not limited to, thyroid cancers, T-ALL (T lineage acute lymphoblastic leukemia), multiple myeloma and Grave's disease. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: October 17, 2022
    Publication date: December 19, 2024
    Inventors: Nai-Kong V. Cheung, James A. Fagin, Hong Fen Guo, Yuchen Jin, Jeffrey Knauf, Gnana Krishnamoorthy, Yiwei Liu, Brian Santich
  • C825 EXPRESSING IMMUNE CELLS AND DIAGNOSTIC USES THEREOF
    Publication number: 20230348853
    Abstract: Provided herein are compositions comprising engineered immune cells that express a tumor antigen-targeted chimeric antigen receptor and an anti-DOTA C825 antigen binding fragment. The engineered immune cells of the present technology are configured to bind to DOTA haptens that may be complexed with a diagnostic radiopharmaceutical (e.g., 111In). Also disclosed herein are methods for determining the in vivo biodistribution, viability, and expansion of the engineered immune cells described herein.
    Type: Application
    Filed: June 28, 2021
    Publication date: November 2, 2023
    Inventors: Steven Larson, Darren Veach, Sarah Cheal, Ouathek Ouerfelli, Guangbin Yang, Simone Krebs, Megan Dacek, David Scheinberg, Nai-Kong Cheung, Brian Santich
  • SYSTEMS FOR IN VIVO MONITORING OF IMMUNE CELLS IN PATIENTS UNDERGOING CELLULAR IMMUNOTHERAPY
    Publication number: 20230346988
    Abstract: The present disclosure provides kits and methods for tracking or monitoring in vivo biodistribution, viability, and/or expansion of immune cells in a cancer patient undergoing cellular immunotherapy.
    Type: Application
    Filed: June 28, 2021
    Publication date: November 2, 2023
    Inventors: Steven Larson, Darren Veach, Sarah Cheal, Ouathek Ouerfelli, Guangbin Yang, Nai-Kong Cheung, Brian Santich, Simone Krebs, Megan Dacek, David Scheinberg
  • COMPOSITIONS INCLUDING EX VIVO ARMED T CELLS WITH MULTI-SPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20230270857
    Abstract: The present disclosure provides ex vivo armed T cell (EAT) compositions that comprise multi-specific (e.g., bispecific) antibodies that bind to CDS and at least one additional target antigen (e.g., antigen that is expressed by tumor cells and/or a DOTA label). The EAT compositions of the present technology are useful for adoptive immunotherapy in a subject in need thereof.
    Type: Application
    Filed: July 27, 2021
    Publication date: August 31, 2023
    Inventors: Jeong A. Park, Nai-Kong V. Cheung, Brian Santich
  • DOTA-HAPTEN COMPOSITIONS FOR ANTI-DOTA/ANTI-TUMOR ANTIGEN BISPECIFIC ANTIBODY PRETARGETED RADIOIMMUNOTHERAPY
    Publication number: 20230256121
    Abstract: The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel compounds that may be complexed with a radioisotope. Also disclosed herein are methods of the using the DOTA-haptens of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.
    Type: Application
    Filed: June 28, 2021
    Publication date: August 17, 2023
    Inventors: Steven Larson, Darren Veach, Sarah Cheal, Ouathek Ouerfelli, Guangbin Yang, Nai-Kong Cheung, Brian Santich, Hong Xu
  • ANTI-CD3 ANTIBODIES AND USES THEREOF
    Publication number: 20230212289
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CD3 protein. The antibodies of the present technology are useful in methods for detecting and treating cancer or a CD3 -associated pathology in a subject in need thereof.
    Type: Application
    Filed: April 23, 2021
    Publication date: July 6, 2023
    Inventors: Nai-Kong V. Cheung, Sayed Shahabuddin Hoseini, Hong Xu, Brian Santich, Mahiuddin Ahmed
  • MULTIMODAL FLUORINE-CY3/5/7-DOTA-HAPTEN COMPOSITIONS, DIAGNOSTICS, FLUORESCENCE GUIDED SURGERY AND RADIOIMMUNOTHERAPY
    Publication number: 20230095707
    Abstract: The present disclosure provides compositions and methods for the detection, and treatment of cancer. Specifically, the compositions of the present technology include multimodal fluorine-cyanine-DOTA-hapten compositions that may be complexed with a radioisotope (e.g., 175Lu). Also disclosed herein are methods of using the fluorine-cyanine-DOTA-hapten compositions of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.
    Type: Application
    Filed: December 30, 2020
    Publication date: March 30, 2023
    Inventors: Nai-Kong V. CHEUNG, Steven M. LARSON, Sarah CHEAL, Richard TING, Hari Krishna KOMMIDI, Feifei AN, Brian SANTICH
  • HETERODIMERIC TETRAVALENCY AND SPECIFICITY ANTIBODY COMPOSITIONS AND USES THEREOF
    Publication number: 20220098329
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., heterodimeric trivalent/tetravalent multispecific antibodies) that specifically bind to three or four distinct target antigens. The immunoglobulin-related compositions described herein are useful in methods for detecting and treating cancer in a subject in need thereof.
    Type: Application
    Filed: November 29, 2019
    Publication date: March 31, 2022
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Brian Santich, Nai-Kong V. Cheung, Morgan Huse